SCHEDULE: Innoviva Boosts Armata Stake, Provides $15M Loan

Innoviva, Inc. and its subsidiary have increased their beneficial ownership in Armata Pharmaceuticals to 83.3% and provided a new $15 million secured loan.

Summary

• Innoviva, Inc. and Innoviva Strategic Opportunities LLC (Reporting Persons) collectively beneficially own 55,467,459 shares of Armata Pharmaceuticals, Inc. Common Stock, representing approximately 83.3% of the outstanding shares.
• This ownership includes 25,076,769 shares of Common Stock, 10,653,847 shares issuable from warrants, and 19,736,843 shares from a convertible loan.
• On August 11, 2025, Armata Pharmaceuticals entered into a new Credit and Security Agreement with Innoviva Strategic Opportunities LLC, borrowing $15,000,000.
• The new loan is a secured term loan facility with an interest rate of 14.00% per annum and a maturity date of January 11, 2029.
• The loan is not convertible into Armata's securities.

Sentiment

Score: 3

Explanation: The filing indicates continued financial support for Armata, which is positive for its operations. However, the very high interest rate on the new loan and the increasing concentration of ownership by Innoviva suggest underlying financial challenges and limited access to more favorable capital, leading to a cautious sentiment.

Positives

• Armata Pharmaceuticals secured an additional $15 million in funding, which can support its operations and strategic initiatives.
• The continued financial support from a major shareholder like Innoviva indicates confidence in Armata's long-term prospects.
• The loan is a secured term loan, providing a clear financing structure.

Negatives

• The 14.00% interest rate on the new $15 million loan is relatively high, indicating potential financial distress or high perceived risk for Armata.
• Armata's increasing reliance on a single major shareholder (Innoviva) for financing could limit its strategic flexibility and expose it to concentrated control.
• The significant beneficial ownership (83.3%) by Innoviva suggests limited public float and potential liquidity issues for other shareholders.

Risks

• High interest rate debt: The 14.00% interest rate on the $15 million loan could strain Armata's cash flow and profitability.
• Concentrated ownership and control: Innoviva's 83.3% beneficial ownership gives it substantial control, potentially limiting the influence of minority shareholders.
• Dependence on a single lender: Armata's reliance on Innoviva for financing could create a single point of failure if Innoviva's financial support changes.
• Potential for future dilution: While the new loan is not convertible, the existing convertible loan and warrants held by Innoviva represent potential future dilution for other shareholders.

Future Outlook

The filing primarily details a change in beneficial ownership and a new debt facility. It does not provide explicit forward-looking statements or guidance regarding Armata's operational or financial performance, beyond the maturity date of the new loan.

Management Comments

• Pavel Raifeld, Chief Executive Officer of Innoviva, Inc. and Innoviva Strategic Opportunities LLC, certified that the information set forth in the statement is true, complete, and correct.

Industry Context

This transaction highlights the ongoing trend of strategic investors taking significant stakes and providing direct financing to smaller biotechnology or pharmaceutical companies, especially those in clinical development that may have limited access to traditional capital markets. The high interest rate suggests Armata may be in a high-risk, high-potential stage, common in the biotech sector where companies often rely on external funding for R&D.

Comparison to Industry Standards

• A 14.00% interest rate for a secured loan is significantly higher than typical corporate debt rates for established companies, reflecting the high-risk profile often associated with clinical-stage biotechnology firms. For example, large pharmaceutical companies like Pfizer or Johnson & Johnson typically secure debt at much lower single-digit rates.
• The beneficial ownership of 83.3% by a single entity (Innoviva) is exceptionally high, far exceeding typical institutional investor stakes in publicly traded companies. This level of control is more akin to a subsidiary or a company undergoing a take-private transaction, rather than a widely held public company. For comparison, even major institutional investors rarely hold more than 10-20% of a large-cap company.
• The repeated amendments to the Schedule 13D and ongoing financing from Innoviva suggest a deep, long-term strategic relationship, potentially indicating a "venture debt" type of arrangement from a strategic partner rather than a traditional bank loan.

Related Party Transactions

• The August 2025 Credit Agreement for $15,000,000 was entered into between Armata Pharmaceuticals, Inc. (Issuer) and Innoviva Strategic Opportunities LLC (Innoviva Sub), which is a wholly-owned subsidiary of Innoviva, Inc., the primary reporting person and major shareholder. This constitutes a related-party transaction due to Innoviva's significant beneficial ownership and control over Armata.

Stakeholder Impact

• Shareholders (excluding Innoviva): Potential for further dilution from existing convertible loans and warrants held by Innoviva. Limited liquidity due to Innoviva's overwhelming beneficial ownership. The high interest rate on the new loan could impact future profitability and shareholder value.
• Employees: Continued funding provides stability for ongoing operations and employment.
• Creditors (other than Innoviva): The new loan is secured, potentially impacting the recovery prospects of other unsecured creditors in a default scenario.

Next Steps

• Armata Pharmaceuticals will continue to service the new $15 million secured loan until its maturity on January 11, 2029.
• Innoviva, Inc. and Innoviva Strategic Opportunities LLC will continue to hold their significant beneficial ownership in Armata Pharmaceuticals.

Key Dates

Recommendation

While the new $15 million loan provides essential funding for Armata, the 14.00% interest rate is a significant concern, indicating financial strain and high perceived risk. Innoviva's overwhelming beneficial ownership (83.3%) suggests limited public float and potential for future dilution from existing convertible instruments. The company's increasing reliance on a single strategic investor for financing, while providing stability, also limits its independence and access to broader capital markets. Given the high cost of capital and concentrated ownership, the stock is a "hold" for existing investors who understand the high-risk, high-reward nature of early-stage biotech, but it is not a "buy" for new investors due to the unfavorable financing terms and governance implications.

Keywords

Armata Pharmaceuticals, Innoviva, Schedule 13D, Beneficial Ownership, Convertible Loan, Warrants, Secured Debt, Biotechnology, Pharmaceuticals, SEC Filing, Corporate Finance, Equity Stake